Analysts predict that AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) will announce earnings per share of ($0.36) for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for AVEO Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.29) and the lowest estimate coming in at ($0.40). AVEO Pharmaceuticals reported earnings per share of ($0.33) in the same quarter last year, which suggests a negative year over year growth rate of 9.1%. The company is scheduled to issue its next quarterly earnings results on Monday, November 8th.
According to Zacks, analysts expect that AVEO Pharmaceuticals will report full year earnings of ($1.65) per share for the current financial year, with EPS estimates ranging from ($1.74) to ($1.58). For the next fiscal year, analysts forecast that the business will report earnings of ($0.30) per share, with EPS estimates ranging from ($0.68) to $0.32. Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for AVEO Pharmaceuticals.
AVEO Pharmaceuticals (NASDAQ:AVEO) last issued its quarterly earnings results on Wednesday, August 4th. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.45) by $0.05. The company had revenue of $7.56 million during the quarter, compared to analyst estimates of $7.76 million. AVEO Pharmaceuticals had a negative net margin of 398.34% and a negative return on equity of 107.25%.
AVEO stock traded down $0.44 during mid-day trading on Wednesday, reaching $6.45. 14,483 shares of the stock traded hands, compared to its average volume of 1,217,686. The stock has a market capitalization of $221.71 million, a PE ratio of -3.32 and a beta of 1.20. AVEO Pharmaceuticals has a one year low of $4.95 and a one year high of $18.24. The company has a debt-to-equity ratio of 0.54, a quick ratio of 6.39 and a current ratio of 6.39. The business has a 50-day moving average price of $5.87 and a two-hundred day moving average price of $6.87.
In other news, CEO Michael P. Bailey purchased 15,000 shares of the company’s stock in a transaction on Wednesday, September 1st. The shares were purchased at an average price of $6.48 per share, with a total value of $97,200.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 3.00% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in AVEO. Eudaimonia Partners LLC bought a new stake in shares of AVEO Pharmaceuticals during the 1st quarter valued at about $48,000. Blueshift Asset Management LLC purchased a new stake in AVEO Pharmaceuticals during the second quarter valued at $67,000. Laurion Capital Management LP purchased a new stake in shares of AVEO Pharmaceuticals in the first quarter valued at $73,000. Verition Fund Management LLC purchased a new position in AVEO Pharmaceuticals in the 1st quarter worth about $84,000. Finally, The Manufacturers Life Insurance Company bought a new position in AVEO Pharmaceuticals during the 1st quarter worth about $97,000. 41.69% of the stock is owned by hedge funds and other institutional investors.
About AVEO Pharmaceuticals
AVEO Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E.
Featured Article: Quick Ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.